8legs: Compass therapeutics, inc.

#1 out of 1100.00%

Compass reports positive COMPANION-002 PFS and ORR results; plans FDA meeting

Compass reports COMPANION-002 shows a significant ORR benefit for tovecimig plus paclitaxel vs paclitaxel alone.
PFS improved to 4.7 months vs 2.6 months with a hazard ratio of 0.44 (p<0.0001).
Overall survival did not reach significance due to high crossover, though pooled OS reached 8.9 months.
Crossover analyses show longer OS for crossover patients (12.8 vs 6.1 months; HR=0.54, p=0.04).
Safety was consistent with prior studies; hypertension and fatigue were common in the combination arm.
Compass plans an FDA meeting to discuss COMPANION-002 results and next steps.
The COMPANION-002 trial enrolled 168 participants to assess tovecimig with paclitaxel.
The study used a crossover design, influencing OS interpretation.
The source material is an AI-powered summary of SEC filings and related disclosures.
TradingView served as the source for the summarized market data on Compass Therapeutics.

Vote 0